Stay updated on Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page
- Check6 days agoChange DetectedA dedicated Locations section was added, listing Washington as a study location. The HHS Vulnerability Disclosure link and the standalone Washington Locations entry were removed, and the revision updated to v3.3.3.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2. No substantive study information appears to change.SummaryDifference0.1%

- Check35 days agoChange DetectedFooter updated to Revision: v3.3.1, replacing the previous Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedTimestamp updates were added to the study record, including Last Update Posted (Estimated) and new date entries such as 2025-10-28, 2025-10, and 2025-11-12. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check56 days agoChange DetectedNo additions or deletions detected; the page content appears unchanged.SummaryDifference0.5%

- Check85 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference3%

Stay in the know with updates to Pembrolizumab in Untreated B-Cell NHL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated B-Cell NHL Clinical Trial page.